Description
A monoclonal antibody called trastuzumab Injection is used to treat stomach and breast cancer. It is only used to treat HER2 receptor-positive tumours.
A monoclonal antibody called trastuzumab Injection is used to treat stomach and breast cancer. It is only used to treat HER2 receptor-positive tumours.
It is recommended that an experienced healthcare provider supervises the subcutaneous or intravenous administration of trastuzumab injection.
Trastuzumab Injection’s most frequent adverse effects are headaches, lightheadedness, joint and muscular discomfort, rash, nausea, dyspnea, dysphagia, soreness at the injection site, allergic reactions, and blood clots.
What components constitute Trastuzumab medication?
The active component in the medication is Trastuzumab, accompanied by inactive ingredients such as α,α-trehalose dihydrate, L-histidine HCl, L-histidine, and polysorbate 20.
Is Hertraz primarily used for breast cancer?
Yes, Hertraz (Trastuzumab 440 mg) Injection serves as a breast cancer treatment.
Has Trastuzumab received FDA approval?
Yes, Trastuzumab Injection has obtained FDA approval.
Is Trastuzumab considered cytotoxic?
Trastuzumab functions as a mediator of antibody-dependent cellular cytotoxicity.